Navigation Links
Biologics Research Promises to Bolster Future of Medicine
Date:3/11/2013

WASHINGTON, March 11, 2013 /PRNewswire-USNewswire/ -- America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

(Logo: http://photos.prnewswire.com/prnh/20091027/PHRMALOGO)

The report includes biologics in human clinical trials or under review by the U.S. Food and Drug Administration such as:

  • 338 cancer therapeutics that target several different types of solid tumors, leukemia and lymphoma;
  • 134 vaccines for infectious diseases;
  • 71 medicines for autoimmune diseases including lupus, multiple sclerosis and rheumatoid arthritis;
  • 58 treatments for cardiovascular disease.

"These medicines reflect the cutting-edge research being conducted across the country by biopharmaceutical companies in order to provide new treatment options to patients," stated PhRMA President and CEO John J. Castellani .

The biologic medicines now in development make use of a range of new technologies to harness scientific progress.  Among the biologic medicines in development are:

  • A genetically-modified virus-based vaccine to treat melanoma;
  • A monoclonal antibody for the treatment of asthma;
  • An antisense therapy for the treatment of leukemia;
  • A recombinant fusion protein to treat type 2 diabetes.

"In order to realize the full potential of novel biologics to improve human health, it is essential to maintain public policy and regulatory environments to support the research and development that drives biomedical innovation," concluded Castellani.

The U.S. biopharmaceutical research sector supports nearly four million jobs across the economy, invests billions of dollars in research and development each year, and accounts for nearly 20 percent of all domestic R&D funded by U.S. businesses generating high-quality, high-wage jobs, powering the U.S. economy, and developing critical new treatments against our most costly and challenging diseases. 

The Biologic Medicines in Development report as well as an overview and other supplementary materials are available on PhRMA's website at http://phrma.org/research/new-medicines.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested over $500 billion in the search for new treatments and cures, including an estimated $49.5 billion in 2011 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit: http://www.innovation.org 
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org   
For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
2. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
3. Employers Becoming Savvier About Biologics and Specialty Drugs
4. Pinnacle Biologics beantragt Zulassung neuer Indikationen in Deutschland und Frankreich
5. Pinnacle Biologics dépose une nouvelle indication pharmaceutique en Allemagne et en France
6. Pinnacle Biologics acquires PDT laser technology
7. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
8. Avaxia Biologics Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative Colitis
9. Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities
10. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
11. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
(Date:5/4/2017)... DIEGO , May 4, 2017  The American ... and Scientific Meeting— OBP Medical , a leading global ... the launch of a new extra-small size and first-in-market ... ER-SPEC vaginal specula. Already available in small, medium, ... makes OBP Medical,s line of single-use lighted specula the ...
Breaking Medicine Technology:
(Date:5/24/2017)... Linda, Ca (PRWEB) , ... May 24, 2017 ... ... between effects and background. Understanind and choosing the most appropriate instruments for research ... prove critical in research finding. This webinar will focus on innovations in stereo ...
(Date:5/24/2017)... ... , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming ... referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on ... no longer need to feel the esthetic effects of wires and brackets when they ...
(Date:5/24/2017)... Michigan (PRWEB) , ... May ... ... disease affecting the female reproductive tract in which the endometrial lining of ... structures causing inflammation and pain. Patients experiencing painful intercourse, painful periods, pelvic ...
(Date:5/24/2017)... ... 2017 , ... Rob Lowe is a sought after actor, and also serves ... the public important topics from all aspects of life, and a new segment is ... feet and ankles. , Podiatry is essential to people’s overall well-being, and if viewers ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and Clinical Integration company, announced today that its iClinic V12.2 solution has achieved ... Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize team-based care with ...
Breaking Medicine News(10 mins):